However, utilizing an Lm-based construct expressing Annexin A2 (Lm-ANXA2), a relevant PDAC tumor antigen, Kim et al., demonstrated that sequential treatment with Lm-ANXA2 followed by PD-1 blockade resulted in an increase in overall survival of PDAC-bearing mice compared with either Lm-ANXA2 or anti-PD-1 therapy alone. This evidence concerns the gene ANXA2 and neoplasm.